News

On September 30, 2025, the U.S. District Court for the Eastern District of Virginia largely denied Amgen’s motion to dismiss in CareFirst of Maryland Inc. et al. v. Amgen Inc. et al., No. 2:24-cv-00484 (E.D. Va.). In this case, Lowey Dannenberg represents CareFirst and a putative class of end payors against Amgen, alleging that Amgen engaged in a years-long scheme…

Lowey Dannenberg, on behalf of named plaintiff Premera Blue Cross, is leading a class on behalf of Third-Party Payers of Amitiza (Lubiprostone) against Takeda Pharmaceutical Company Ltd. and related entities. Plaintiff allege that drug manufacturers Takeda and Sucampo, acting as partners, reached an anticompetitive agreement with generic manufacturer Par Pharmaceutical, Inc. in 2014, under which Par would delay market entry…

Lowey Dannenberg, P.C. is pleased to welcome its newest partner, Joseph Nielsen, to the firm. Joe built a storied career in private and public roles representing victims of antitrust conspiracies in the technology and pharmaceutical industries. During his 19 years at the Connecticut Attorney General’s Office, Joe gained extensive experience building antitrust cases from the ground up. After years of…

Lowey Dannenberg, P.C., is thrilled to welcome our newest partner, Matthew A. Cartwright. Matt has long distinguished himself as a trial lawyer and a public servant, and now brings his skills to Lowey.   He joins Lowey’s Healthcare Litigation Team and will be based in the Pennsylvania office in West Conshohocken.   After beginning his career in the litigation department at a…

On May 14, 2021, Judge Nathaniel M. Gorton of the U.S. District Court for the District of Massachusetts granted the End-Payor Plaintiffs’ (“EPPs’”) class certification motion. The EPPs are third party payors paying some or all of the purchase price for prescription drugs, including commercial insurers and health plan sponsors. The EPPs allege that Ranbaxy’s wrongful acquisition of tentative approval…